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Abstract 
Single nucleotide polymorphisms (SNPs) in the IL28B gene were shown to have limited utility in predicting response 
to telaprevir and boceprevir in treatment of chronic HCV infection in clinical trials. Data outside of the clinical trial 
setting are lacking. We assessed the value of single and combined IL28B SNPs rs12979860 and rs8099917 genotypes 
in predicting sustained virological response 12 weeks after cessation of triple therapy (SVR12) with telaprevir or 
boceprevir in a single-centre cohort of treatment-naïve and treatment-experienced patients with genotype 1 HCV 
mono-infection (n = 105). The overall SVR12 rate was 65.7%. By unadjusted bivariate logistic regression analysis, 
rs12979860-CC and rs8099917-TT were significantly associated with SVR12 in the subgroup of patients including all 
naïve patients and all treatment-experienced patients with the exception of partial- and null-responders to previ-
ous HCV therapy. The predictive value of rs12979860-CC was stronger than rs8099917-TT and only rs12979860-CC 
remained significantly predictive of treatment success when the two variants were assessed by adjusted logistic 
regression analysis in the whole study cohort. In patients presenting the rs12979860-CC variant, the additional 
determination of rs8099917 genotype had no value. IL28B rs12979860-CC remained significantly associated with 
SVR12 also in the multivariate analysis including the other baseline characteristics associated to SVR12 in the bivariate 
analysis (i.e., female gender, HCV genotype 1b, baseline viral load <800,000 IU/mL, advanced liver fibrosis and prior 
partial- or null-response to HCV therapy). Our study suggests that testing for the IL28B rs12979860 genotype may 
still be useful in predicting response to triple therapy with boceprevir and telaprevir in naïve patients and treatment-
experienced patients other than partial and null-responders.
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Background
In 2009, genome-wide association studies showed 
that single nucleotide polymorphisms (SNPs) located 
upstream the gene for interleukin-28 (IL28B) on chro-
mosome 19 were strongly associated with sustained 
virological response (SVR) to hepatitis C virus (HCV) 
treatment with pegylated interferon alpha PEG-IFN 
and ribavirin RBV (Ge et  al. 2009; Suppiah et  al. 2009; 
Tanaka et  al. 2009). SNPs at rs12979860 and rs8099917 
were identified: favourable outcome were seen with CC 
at rs12979860 compared to non-CC genotypes (CT or 
TT), and unfavourable outcome were seen with GG or 
GT genotypes at rs8099917. The IL28B gene encodes 
for a protein named interferon-lambda-3, a type III 
interferon (IFN). The precise molecular mechanism 
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underlying the influence of IL28B polymorphism on 
response to PEG-IFN/RBV treatment for hepatitis C 
remains elusive. Based on the observation that patients 
carrying the unfavourable IL28B genotypes seem to have 
an inappropriately up-regulated intrahepatic expression 
of interferon-stimulated genes (ISGs), some authors have 
hypothesised that those with a favourable IL28B pro-
file, having a lower intrahepatic ISGs expression, may be 
more sensitive to exogenous IFN and, thus, more likely 
to respond to treatment and to eradicate the infection 
(Honda et al. 2010; Urban et al. 2010).
Two years after the influence of IL28B SNPs was 
described, the first-generation protease inhibitors 
boceprevir and telaprevir were approved for treatment 
of genotype 1 chronic HCV infection in combination to 
PEG-IFN/RBV. These drugs substantially improved SVR 
rates for genotype 1 HCV in both naïve and treatment-
experienced patients (Poordad et  al. 2011; Jacobson 
et al. 2011; Bacon et al. 2011; Zeuzem et al. 2011; Pearl-
man 2012). The increased potency of these new directly 
acting agents (DAAs), has, however led some to ques-
tion whether IL28B genotype testing still has any value 
(Jensen and Pol 2012). Retrospective analyses of phase-3 
clinical trials of telaprevir and boceprevir have been con-
ducted to evaluate the utility of IL28B genotype testing, 
but there are limited data outside clinical trials (Poordad 
et al. 2012; Pol et al. 2013; Jacobson et al. 2011).
This study assessed the value of two IL28B SNPs, 
rs12979860 and rs8099917, in predicting SVR to tel-
aprevir or boceprevir triple therapy 12  weeks after 
treatment cessation (SVR12) in a single-centre cohort 
of previous HCV treatment-naïve and treatment-expe-




Patients with genotype 1 chronic HCV infection 
who received PEG-IFN/RBV and either telaprevir or 
boceprevir at The Royal Free London NHS Foundation 
Trust (UK) between June 2011 and December 2012 and 
had IL28B SNPs testing were included in the study. Prior 
to June 2012, patients started triple therapy through an 
expanded access programme (EAP) preceding approval 
of telaprevir and boceprevir by the National Institute 
for Health and Clinical Excellence (NICE). Patients co-
infected with HIV or HBV and patients infected with 
HCV genotypes other than 1 were excluded. All patients 
were treated in accordance with the manufacturer’s pre-
scribing instructions.
Institutional review board approval was not required 
for this study as patients were treated with approved 
diagnostic and therapeutic procedures according to 
generally accepted standards of care and all data col-
lected retrospectively were fully de-identified.
Data collection
Demographic, clinical and virological characteristics 
were collected retrospectively reviewing the clinical 
notes and the electronic laboratory reporting system.
Liver fibrosis was evaluated by liver biopsy performed 
within 24  months prior to treatment initiation in 45% 
of patients and by transient elastography in 25.8% of 
patients. In the remaining 29.2% of patients no liver 
biopsy or transient elastography was done because the 
diagnosis of liver cirrhosis was clear from routine clini-
cal-radiological assessment. Fibrosis stage was catego-
rised according to the METAVIR score. Where fibrosis 
was assessed by transient elastography the following 
cut-off values were used: <7.1 kilopascal (kPa) for META-
VIR F0–F1, 7.1–9.4 kPa for F2, 9.5–12.4 kPa for F3 and 
>12.5 kPa for F4 (Castera et al. 2005). All patients diag-
nosed with liver cirrhosis in the routine clinical-radiolog-
ical assessment were classified as METAVIR F4.
As far as previous HCV treatment is concerned, 
patients were considered ‘naïve’ if they had no previous 
treatment with PEG-IFN/RBV, ‘null-responders’ if they 
failed previous HCV treatment with a viral load (VL) 
decrease of <2 log10 IU/mL, ‘partial responders’ if they 
had a >2 log10 drop in VL but failed to clear the virus, 
‘virological breakthrough’ if they achieved an undetect-
able VL initially but became viraemic again whilst on 
treatment, ‘relapsers’ if they achieved an undetectable 
HCV VL at the end of treatment (EOT) but relapsed 
during the subsequent 24-week follow-up and ‘interrup-
tion due to side effects (SEs)’ if discontinued prematurely 
treatment due to adverse reactions.
Outcomes
SVR12, defined as undetectable HCV VL at week 12 of 
follow-up after end of triple therapy treatment, was the 
primary outcome in our intention-to-treat analysis. The 
secondary outcome was a shortened course of triple ther-
apy among patients considered eligible.
Measurements
HCV RNA was extracted from 1.5 mL of serum or plasma 
using the QiaSymphony platform (Qiagen, Crawley, UK) 
and HCV RNA VL was quantified using a validated in-
house real-time PCR (RT-PCR) assay that amplifies a 
portion of the highly conserved 5′ untranslated region 
(UTR) of HCV. The assay has a lower limit of quantifica-
tion of 12 IU/mL.
Human genomic DNA was extracted from plasma sam-
ples using the QiaSymphony mini DNA blood extraction 
kit. RT-PCR was performed for two single nucleotide 
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polymorphisms (SNPs) within the IL28B locus (C or T 
for rs12979860 and G or T for rs8099917) using TaqMan 
allelic discrimination assay, as previously described.
Statistical analysis
Firstly, we compared the distribution of baseline character-
istics and the differences in SVR12 rates in patients receiv-
ing triple therapy through the EAP and patients treated 
after telaprevir and boceprevir were introduced in the UK 
market. Since no significant difference in SVR12 rates were 
observed in the two groups, we proceeded to analyse the 
study cohort as a whole and we evaluated the significance 
of associations between the study population’s baseline 
characteristics, including the different IL28B SNPs, and 
SVR12 rates to triple therapy. Patients naïve to previous 
HCV treatment were compared to the rest of the study 
cohort (all treatment-experienced patients). Each treat-
ment-experienced subgroup (i.e., previous interruption 
due to SEs, viral breakthrough, relapsers, partial-respond-
ers and null-responders) was compared separately to naïve 
patients. Because no significant differences in outcomes 
between boceprevir and telaprevir groups were observed, 
all patients were analysed as one cohort. Two-tailed Pear-
son’s Chi squared, Fisher’s exact and Mann–Whitney U 
tests were used in the bivariate analyses. Hardy–Weinberg 
equilibrium of observed versus predicted IL28B geno-
type frequencies and the degree of linkage disequilibrium 
between the two SNPs were assessed by two-tailed Pear-
son’s Chi squared test. P values of <0.05 were considered to 
be statistically significant.
All factors significantly associated with SVR12 in the 
bivariate analyses were included in the multivariate 
logistic regression analyses. For the multivariate logis-
tic regression analysis, we dichotomised previous HCV 
treatment categories in two groups:
1. One group including naïve patients, patients who 
interrupted treatment due to SEs and prior virologi-
cal breakthrough and relapsers;
2. another group including prior partial and null 
responders.
We also dichotomised HCV genotype categories in one 
group including only genotype 1b and the other group 
comprising genotype 1a and all patients with genotype 1 
where subtyping was not done.
Finally, we assessed by unadjusted and adjusted logis-
tic regression analysis the associations between the 
rs12979860-CC and the rs8099917-TT genotypes and 
SVR12 in the two previous HCV treatment sub-groups. 
We also calculated sensitivity, specificity, positive predic-
tive value (PPV) and negative predictive value (NPV) of 
the two favourable IL28B variants in relation to SVR12.
Data analysis was performed using Stata v12 (Stata-
Corp LP, College Station, TX, USA).
Results
Overall, 105 patients with HCV genotype 1 infection 
started triple therapy with either telaprevir or boceprevir 
during the study period. Around half (50.5%) of the 
patients in our cohort, started triple therapy through the 
EAP. Differences in the baseline characteristics between 
patients enrolled in the EAP and patients selected for 
triple therapy following formal launch of telaprevir and 
boceprevir in the UK market are summarised in Table 1. 
Patients treated through the EAP were older (p = 0.010), 
more likely to be treatment-experienced (p = 0.001) and 
null-responders (p = 0.038) to previous HCV therapy. A 
smaller proportion of patients treated through the EAP 
achieved SVR12 compared to patients treated outside of 
the EAP (60.4 vs 71.2%) but this difference was not statis-
tically significant (p = 0.245).
Baseline characteristics, including distribution of the 
two IL28B SNP genotypes, and their associations with 
SVR 12 for the whole cohort of 105 patients are shown 
in Table  2. Most patients (72.4%). in the study cohort 
were treatment-experienced and 29.7% were partial or 
null responder to previous HCV therapy. Almost half 
(47.6%) of all patients had advanced fibrosis (METAVIR 
F3 or F4). Whilst the genotypic frequencies of the IL28B 
SNP at rs8099917 were in Hardy–Weinberg equilib-
rium, the genotypic frequencies of rs12979860 were not 
(p = 0.007), with more CT genotypes and less CC geno-
types observed than expected. Strong linkage disequi-
librium between IL28B s12979860 and rs8099917 was 
observed (p < 0.001). All 23 patients who had genotype 
CC at rs12979860 had also genotype TT at rs8099917, 
whereas only 51.1% (23/45) of patients with genotype 
TT at rs8099917 had genotype CC at rs12979860, the 
remaining 48.9% (22/45) being genotype CT. The pro-
portion of genotype CC at rs12979860 was lower among 
partial- and null-responder to previous HCV treatment 
compared to the rest of the cohort (9.7 vs 27%, p = 0.050) 
(Figure 1).
The overall SVR12 rate in our mixed cohort of treat-
ment-naïve and treatment-experienced patients was 
65.7%. Of the 36 patients who failed to achieve SVR12 
to triple therapy, 9 patients (8.6% of the whole cohort) 
stopped because of side effects. Treatment was stopped 
due to side effects in 1 out of 17 patients started on 
boceprevir and 8 out of 88 patients started on telaprevir 
(p  =  1.000). Side effects leading to treatment interrup-
tion were severe dermatitis in 2 patients, mental health 
problems in 2 patients, gastrointestinal intolerance in 2 
patients, neutropaenic sepsis in 1 patient, severe anaemia 
and fatigue in 1 patient and IFN-associated retinopathy 
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in another patient. Overall, 42.9% of patients (45/105) 
required either PEG-IFN or RBV dose reductions, the 
most common reasons being anaemia (25 patients), 
thrombocytopenia (11 patients) and neutropaenia (5 
patients).
No significant differences in SVR12 rates were observed 
between patients who had their PEG-IFN or RBV dose 
modified compared to the rest of the study cohort (60.0 
vs 70.0%, p = 0.389).
Among the baseline characteristics examined, female 
gender (p =  0.037), a history of relapse following pre-
vious HCV treatment (p  =  0.020), HCV genotype 
1b (p =  0.001), a HCV VL lower than 800,000  IU/mL 
(p  =  0.016) and IL28B genotype CC at rs12979860 
(p = 0.015) were all significantly associated with SVR12, 
whereas advanced liver fibrosis (p  =  0.046), a history 
of prior null-response to PEG-IFN/RBV (p  =  0.008) 
or the status of prior partial or null-responder to pre-
vious HCV therapy (p  =  0.001) were all significantly 
associated to a non-response to triple therapy (Table 2). 
In our study, there was no added value in combin-
ing IL28B genotype CC at rs12979860 and genotype 
TT at rs8099917 testing compared to genotype CC at 
rs12979860 testing alone.
Table 1 Baseline characteristics and SVR12 rates in patients started on treatment through the EAP and patients started 
on treatment outside the EAP
Variable All patients  
(n = 105)
Treated through the  
EAP (n = 53)
Treated outside the  
EAP (n = 52)
P value
Gender, female (n, %) 31 (29.5) 15 (28.3) 16 (30.8) 0.782
Age, years (median, IQR) 52 (10) 53 (9) 50 (7) 0.010
Age, <52 years (n, %) 46 (43.8) 18 (34.0) 28 (53.8) 0.04
Ethnicity
 White/Caucasian (n, %) 86 (81.9) 45 (84.9) 41 (78.8) 0.298
 Black (n, %) 6 (5.7) 3 (90.6) 3 (5.8) 0.981
 Other (n, %) 13 (12.3) 5 (9.5) 8 (15.4) 0.355
Liver fibrosis
 Non-advanced, i.e. METAVIR F0-F2 (n, %) 55 (52.4) 24 (45.3) 31 (59.6) 0.141
 Advanced, i.e. METAVIR F3 or F4 (n, %) 50 (47.6) 29 (54.7) 21 (40.4)
Previous HCV treatment
 Naïve 29 (27.6) 6 (11.3) 23 (44.2) 0.001
 Interruption due to side effects 5 (4.8) 2 (3.8) 3 (5.8) 0.631
 Viral breakthrough 7 (6.7) 6 (11.3) 1 (1.9) 0.113
 Relapser 33 (31.4) 18 (34.0) 15 (28.8) 0.572
 Partial responder 8 (7.6) 5 (9.4) 3 (5.8) 0.479
 Null responder 23 (21.9) 16 (30.2) 7 (13.5) 0.038
HCV protease inhibitor
 Boceprevir (n, %) 17 (16.2) 11 (20.7) 6 (11.6) 0.200
 Telaprevir (n, %) 88 (83.8) 42 (79.3) 46 (88.4)
HCV genotype
 1a 45 (42.9) 24 (45.3) 21 (40.4) 0.281
 1b 43 (40.9) 18 (34.0) 25 (48.1)
 1 non-subtyped 17 (16.2) 11 (20.7) 6 (11.5) 0.290
HCV viral load, IU/mL (median, IQR) 1,833,451 (3,459,687) 1,893,740 (3,480,802) 1,588,705 (3,024,102) 0.423
HCV viral load, <800,000 IU/mL (n, %) 30 (28.5) 14 (26.4) 16 (30.8) 0.621
IL28B rs12979860 genotype
 CC (n, %) 23 (21.9) 8 (15.1) 15 (28.8) 0.088
 CT (n, %) 67 (63.8) 37 (69.8) 30 (57.7) 0.196
 TT (n, %) 15 (14.3) 8 (15.1) 7 (13.5) 0.811
IL28B rs8099917 genotype
 TT (n, %) 45 (42.8) 22 (41.5) 23 (44.2) 0.778
 GT (n, %) 51 (48.6) 28 (52.8) 23 (44.2) 0.378
 GG (n, %) 9 (8.6) 3 (5.7) 6 (11.6) 0.319
SVR12 to triple therapy 69 (65.7) 32 (60.4) 37 (71.2) 0.245
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Table 2 Baseline characteristics associated with SVR12 to triple therapy
Baseline characteristics All patients  
(n = 105)
Patients who achieved  
SVR12 to triple  
therapy (n = 69)
Patients who did  
not achieve SVR12  
to triple therapy (n = 36)
P value
Gender, female (n, %) 31 (29.5) 25 (36.2) 6 (16.6) 0.037
Age, years (median, IQR) 52 (10) 52 (16) 53 (8) 0.151
Age, <52 years (n, %) 46 (43.8) 33 (47.8) 13 (36.1) 0.251
Ethnicity
 White/Caucasian (n, %) 86 (81.9) 58 (84.1) 28 (77.8) 0.550
 Black (n, %) 6 (5.7) 2 (2.9) 4 (11.1) 0.085
 Other (n, %) 13 (12.3) 9 (13) 4 (11.1) 0.775
Liver fibrosis
 Non-advanced, i.e. METAVIR F0-F2 (n, %) 55 (52.4) 41 (59.4) 14 (38.9) 0.046
 Advanced, i.e. METAVIR F3 or F4 (n, %) 50 (47.6) 28 (40.6) 22 (61.1)
Previous HCV treatment
 Naïve 29 (27.6) 22 (31.9) 7 (19.4) 0.340
 Interruption due to side effects 5 (4.8) 3 (4.3) 4 (11.1) 0.783
 Viral breakthrough 7 (6.7) 3 (4.3) 4 (11.1) 0.393
 Relapser 33 (31.4) 28 (40.6) 5 (13.9) 0.020
 Partial responder 8 (7.6) 4 (5.8) 4 (11.1) 0.587
 Null responder 23 (21.9) 9 (13) 14 (38.9) 0.008
 Naïve, interruption due to side effects, viral  
breakthrough and relapsers (n, %)
74 (70.5) 56 (81.2) 18 (50.0) 0.001
 Partial and null responders (n, %) 31 (29.5) 13 (18.8) 18 (50.0)
HCV protease inhibitor
 Boceprevir (n, %) 17 (16.2) 13 (18.8) 4 (11.1) 0.307
 Telaprevir (n, %) 88 (83.8) 56 (81.2) 32 (88.9)
HCV genotype
 1a 45 (42.9) 21 (30.4) 24 (66.7) 0.001
 1b 43 (40.9) 35 (50.7) 8 (22.2)
 1 non-subtyped 17 (16.2) 13 (18.8) 4 (11.1) 0.307
 1a and 1 non-subtyped (n, %) 62 (59.1) 34 (49.3) 28 (77.8) 0.005
 1b (n, %) 43 (40.9) 35 (50.7) 8 (22.2)
HCV viral load, IU/mL (median, IQR) 1,833,451 (3,459,687) 1,417,630 (2,505,928) 2,115,100 (4,038,313) 0.005
HCV viral load, <800,000 IU/mL (n, %) 30 (28.5) 25 (36.2) 5 (13.9) 0.016
IL28B rs12979860 genotype
 CC (n, %) 23 (21.9) 20 (29) 3 (8.3) 0.015
 CT (n, %) 67 (63.8) 42 (60.9) 25 (69.4) 0.385
 TT (n, %) 15 (14.3) 7 (10.1) 8 (22.2) 0.093
IL28B rs8099917 genotype
 TT (n, %) 45 (42.8) 34 (49.3) 11 (30.5) 0.066
 GT (n, %) 51 (48.6) 31 (44.9) 20 (55.6) 0.301
 GG (n, %) 9 (8.6) 4 (5.8) 5 (13.9) 0.160
Combinations of IL28B SNPs
 rs12979860-CC and rs8099917-TT (n, %) 23 (21.9) 20 (29) 3 (8.3) 0.015
 rs12979860-CC and rs8099917-GT (n, %) 0 0 0 /
 rs12979860-CC and rs8099917-GG (n, %) 0 0 0 /
 rs12979860-CT and rs8099917-TT (n, %) 22 (20.9) 14 (20.3) 8 (22.2) 0.514
 rs12979860-CT and rs8099917-GT (n, %) 45 (42.9) 28 (40.6) 17 (47.2) 0.817
 rs12979860-CT and rs8099917-GG (n, %) 0 0 0 /
 rs12979860-TT and rs8099917-TT (n, %) 0 0 0 /
 rs12979860-TT and rs8099917-GT (n, %) 6 (5.7) 3 (4.3) 3 (8.3) 0.404
 rs12979860-TT and rs8099917-GG (n, %) 9 (8.6) 4 (5.8) 5 (13.9) 0.160
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On multivariate logistic regression analysis, HCV gen-
otype 1b (OR 3.4, 95% CI 1.20–9.51) and IL28B genotype 
CC at rs12979860 (OR 7.4, 95% CI 1.70–32.08) remained 
significantly associated with SVR12 to triple therapy, 
whereas advanced liver fibrosis (OR 0.3, 95% CI 0.12–
0.89) and a history of previous partial or null-response 
to PEG-IFN/RBV treatment (OR 0.3, 95% CI 0.12–0.94) 
remained significantly associated with failure to achieve 
SVR12 to triple therapy (Table 3).
In the unadjusted logistic regression subgroup analy-
sis according to previous HCV treatment history, both 
IL28B 12979860-CC genotype and rs8099917-TT geno-
type were significantly associated with SVR12 in the 
group including patients naïve, patients who interrupted 
treatment due to SEs, patients with a history of viral 
breakthrough or relapse (OR 7.3 and 4.34, respectively) 
(Table 4). No significant association was found between 
any of the SNPs and SVR12 in the subgroup including 
partial and null responders to previous HCV therapy.
In the adjusted regression analysis including both 
favourable SNPs, IL28B 12979860-CC maintained is sig-
nificant association with SVR12 in the whole cohort and 
a trend towards significance was observed also in the 
subgroup of patients naïve, interruption due to SEs, viro-
logical breakthrough and relapsers, whereas the associa-
tion between rs8099917-TT and SVR12 disappeared in 
all treatment groups (Table 4).
PPV of IL28B genotype CC at rs12979860 in relation to 
the likelihood of achieving SVR12 was 87% (95% CI 65.3–
96.6%) in the whole study cohort, 95% (95% CI 73.1–
99.7%) in the group including patients naïve, patients 
who interrupted treatment due to SEs and patients with a 
history of viral breakthrough during treatment or relapse 
after EOT. PPV of genotype rs8099917-TT in relation to 
SVR12 was 75.6% (95% CI 60.1–86.6) in the whole study 
cohort and 88.6% (95% CI 72.3–96.3) in the group includ-
ing patients naïve, patients who interrupted treatment 
due to side effects and patients with a history of viral 
breakthrough during treatment or relapse after EOT.
Five out of 7 and 25 out of 34 patients considered eli-
gible at baseline received a shortened course of therapy 
with boceprevir and telaprevir, respectively. Overall 
duration of triple therapy could be shortened in 73.2% of 
patients. None of the baseline characteristics, including 
IL28B genotype CC at rs12979860, was significantly asso-
ciated with the likelihood of receiving a shortened course 
of triple therapy.
Conclusions
There is a lack of published data on the utility of IL28B 
genotyping in predicting SVR to triple therapy with tel-
aprevir and boceprevir. In our cohort, IL28B genotype 
CC at rs12979860 and genotype TT at rs8099917 were 
significantly associated with SVR12 and predicted suc-
cessful virological cure following triple therapy in the 
subgroup of patients comprising both patients naïve to 
previous therapy and patients who failed prior treatment 
but showed the ability to respond to PEG-IFN/RBV (i.e., 
previous virological breakthrough and relapsers).
Poordad et  al. (2012) reviewed the factors associ-
ated with SVR in the boceprevir studies SPRINT-2 
on treatment-naïve patients and RESPOND-2, on 
Figure 1 Distribution of the different IL28B rs12979860 variants according to prior hepatitis C therapy group.
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treatment-experienced patients. The CC genotype at 
rs12979860 was independently associated with SVR in 
SPRINT-2 but not in RESPOND-2. In both studies, the 
rs12979860-CC genotype was associated strongly with 
a good response to interferon at week 4 (>1 log10 VL 
decline after the lead-in phase) and could therefore be 
used to identify patients eligible for shorter treatment 
duration. This association, however, disappeared in 
the multivariate regression analysis. In the ADVANCE 
study, which evaluated telaprevir for naïve patients, 
rs12979860-CC genotype patients were more likely to be 
eligible for shortened duration of treatment and achieve 
an eRVR (Jacobson et  al. 2011). Finally, in treatment-
failure patients treated with telaprevir-based therapy 
(REALIZE study), IL28B did not significantly affect SVR 
in the multivariate analysis (Pol et al. 2013).
In our study, the predictive value of both IL28B poly-
morphisms in relation to the likelihood of achieving 
SVR12 to triple therapy was seen only in the sub-group 
including the patients with favourable prior HCV treat-
ment history (i.e., naïve, patients who interrupted treat-
ment due to SE, patients with a history of virological 
breakthrough during treatment or relapse after EOT). 
These findings are comparable with the results of the 
clinical trials, which reported a significant effect of IL28B 
genotype only in treatment naïve individuals (Poordad 
et al. 2012; Jacobson et al. 2011).
In this study, rs12979860-CC was a stronger predic-
tor of SVR12 than rs8099917-TT. In patients present-
ing the rs12979860-CC, the additional determination of 
rs8099917 genotype had no value. When the two variants 
were compared directly by multivariate logistic regres-
sion analysis, only rs12979860-CC remained significantly 
associated to treatment success. Our results are in line 
with several larger studies conducted in patients treated 
with the combination PEG-IFN/RBV (Bochud et al. 2011; 
Fischer et al. 2012).
Table 3 Multivariate logistic regression analysis of  base-
line characteristics significantly associated with  SVR12 
to triple therapy in the bivariate analysis
OR odds ratio, CI confidence intervals.
Variable Association with SVR12 
to triple therapy
OR 95% CI P value
Gender female 1.4 0.42–4.50 0.594
Advanced liver fibrosis (METAVIR F3 or F4) 0.3 0.12–0.89 0.029
Partial or null-responders to previous HCV 
therapy
0.3 0.12–0.94 0.039
HCV genotype 1b 3.4 1.20–9.51 0.021
Baseline HCV viral load <800,000 IU/mL 3.0 0.89–10.22 0.076
IL28B rs12979860-CC 7.4 1.70–32.08 0.007
Table 4 Unadjusted and  adjusted logistic regression analysis of  the associations between  IL28B rs12979860-CC 
and rs8099917-TT and SVR12 to triple therapy according to previous HCV treatment group
Sensitivity, specificity, PPV, NPV of the two favourable IL28B variants in relation to SVR12.
OR odds ratio, CI confidence intervals, PPV positive predictive value, NPV negative predictive value.
All patients  
(105 patients)
Naïve, interruption due  
to SEs, viral breakthrough  
and relapsers (74 patients)
Partial and null  
reponders  
(31 patients)
SVR12 (95% CI) 65.7% (56.6–74.8) 75.7% (65.9–85.5) 41.9% (24.5–59.3)
IL28B rs12979860-CC
 Frequency (95% CI) 21.9% (14.0–29.8) 27% (16.9–37.1) 9.7% (0.0–20.1)
 Unadjusted OR (95% CI) 4.4 (1.23–16.33) 8.7 (1.08–70.67) 0.67 (0.05–8.24)
 Adjusted OR (95% CI) 3.97 (1.07–14.72) 7.3 (0.88–61.18) 0.59 (0.47–7.43)
 Sensitivity (95% CI) 29.0% (19.0–41.3) 33.9% (22.2–47.9) 7.7% (0.4–37.9)
 Specificity (95% CI) 91.7% (76.4–97.8) 94.4% (70.6–99.7) 88.9% (63.9–98.1)
 PPV (95% CI) 87.0% (65.3–96.6) 95.0% (73.1–99.7) 33.3% (1.8–87.5)
 NPV (95% CI) 40.2% (29.7–51.7) 31.5% (19.9–45.7) 57.1% (37.4–75.0)
IL28B rs8099917-TT
 Frequency (95% CI) 42.8% (33.4–52.4) 47.3% (35.9–58.7) 32.3% (15.8–48.8)
 Unadjusted OR (95% CI) 2.20 (0.94–5.17) 4.3 (1.27–14.84) 0.47 (0.10–2.34)
 Adjusted OR (95% CI) 0.52 (0.17–14.72) 0.46 (0.12–1.82) 0.39 (0.04–4.35)
 Sensitivity (95% CI) 49.3% (37.1–61.5) 55.4% (41.6–68.4) 23.1% (6.2–54.0)
 Specificity (95% CI) 69.4% (51.7–83.1) 77.8% (51.9–92.6) 61.1% (36.1–81.7)
 PPV (95% CI) 75.6% (60.1–86.6) 88.6% (72.3–96.3) 30.0% (8.1–64.6)
 NPV (95% CI) 41.7% (29.3–55.1) 35.9% (21.7–52.8) 52.4% (30.3–73.6)
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Because around half of our study population was 
started on treatment through the EAP, the results of 
this study may not be entirely generalizable to the “real-
world”. Although patients enrolled through the EAP may 
have been more difficult to cure because older and more 
likely to be treatment-experienced and null-responder 
to previous HCV therapy, we cannot exclude a selection 
bias whereby the treating physicians may have preferen-
tially enrolled in the EAP the most motivated patients. 
This could explain why, even in this subgroup of patients 
where over 90% of subjects were treatment-experienced 
and the majority had advanced liver fibrosis, a SVR12 
rate of 60.4% was observed. This is higher than the cure 
rate reported by the two largest “real-world” case series 
of patients treated with telaprevir- or boceprevir-based 
triple therapy published to date: Ioannou et  al. (2014) 
analysis of the Veterans Administration (VA) healthcare 
system cohort and Price et  al. (2014) analysis of North-
ern California Kaiser Permanente (KPNC) cohort. Since 
compliance was not consistently noted for all patients 
and throughout the study period, we are unable to prove 
the link between this hypothetical selection bias and the 
increased SVR12 rate. Other differences in cohort com-
position could explain our greater SVR12 rate. The VA 
cohort had a greater proportion of men (96 vs 70.5%) and 
a smaller proportion of patients infected with HCV geno-
type 1b (21.3 vs 48.9%, considering only patients who had 
genotype 1 subtyping performed) (Ioannou et  al. 2014). 
In the KPNC cohort HCV genotype 1b was less frequent 
than in our study population (33.7 vs 48.9%, considering 
only patients who had genotype 1 subtyping performed) 
and the proportion of black individuals was greater (15 
vs 5.7%) (Price et al. 2014). IL28B genotype composition 
was not reported in the KPNC study, however, because 
the CC profile at rs12979860 is less common among 
black patients, it is possible that a smaller proportion 
of patients had the most favourable profile (Clark et  al. 
2011).
In summary, our study suggests that, outside the 
clinical trials setting, IL28B testing genotype CC at 
rs12979860 remains predictive of SVR12 to telaprevir- 
and boceprevir-based triple therapy. Similar to the retro-
spective analyses of phase-3 clinical trials, the predictive 
value of rs12979860-CC was observed only in patients 
in the most favourable previous HCV treatment cat-
egories, such as naïve patients, subjects that interrupted 
PEG-IFN/RBV therapy due to adverse events, prior viral 
breakthrough and relapsers. More efficacious and better-
tolerated DAAs are now available. Although preliminary 
data suggest that patients with a favourable IL28B gen-
otype seem to have slightly better chances of cure even 
with some interferon-free combinations, the influence of 
IL28B is likely to fade away when SVR rates approaches 
>90% in all patients (Holmes et  al. 2012). In countries 
where this new wave of DAAs is already replacing tel-
aprevir and boceprevir, testing for IL28B may be consid-
ered futile. However, in those settings where the use of 
the newer DAAs will be restrained for some time due to 
limited economic resources, testing for IL28B genotype 
may still be used, in addition to other baseline predictors, 
to identify patients that can be successfully treated with 
the telaprevir- and boceprevir-based treatment regimens.
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